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Kratak sadr`aj: Primena metotreksata (MTX) u viso kim
dozama i/ili intratekalno u terapiji malignih obo ljenja poput
akutne limfoblasti~ne leukemije (ALL) povezana je sa poja -
vom blagih ili te{kih oblika neuro toksi~nosti. Patogeneza
neurotoksi~nosti nije u potpu nosti razja{njena, ali se va`na
uloga pripisuje biohe mijskim promenama folatnog i metil-
transfernog meta boli~kog puta za koje se smatra da su uzro -
kovane dejstvom MTX. Opisujemo slu~aj odrasle pacijen tki -
nje na terapiji recidiva ALL sa simptomima hroni~ne leu -
koencefalopatije najverovatnije uzrokovane primenom MTX.
U cilju procene folatnog i metil-transfernog puta u cere bro -
spinalnoj te~nosti (CST) pacijentkinje merene su koncen -
tracije 5-metiltetrahidrofolata (5-metil-THF), S-adenozilme -
tionina (SAM) i S-adenozilhomocisteina (SAH). Tri uzorka
CST su dobijena lumbalnom punkcijom u periodu od ~etiri
meseca. Koncentracije su merene pomo}u validiranih bio -
ana liti~kih metoda zasnovanih na primeni HPLC sa ultra -
ljubi~astom i fluorescentnom detekcijom. Rezultati su poka -
zali dvostruko sni`enje koncentracije 5-metil-THF (29.3–
31.8 nmol/L) u pore|enju sa referentnim vrednostima u
svim uzor cima, dok su koncentracije SAM bile pet puta
manje u dva uzorka (5–34.2 nmol/L). Koncentracije SAH su
bile u rasponu 7.5–14.3 nmol/L. Na{a pacijentkinja je imala
izra`ene promene u folatnom i metil-transfernom metabo -
li~kom putu koje uka zuju na to da biohemijske promene ovih
metaboli~kih puteva za koje se smatra da su uzrokovane
dejstvom MTX mogu igrati va`nu ulogu u razvoju leuko ence -
falopatije. 
Klju~ne re~i: metotreksat, cerebrospinalna te~nost, 5-me -
tiltetrahidrofolat, S-adenozilmetionin, neurotoksi~nost
Summary: Intrathecal and/or high-dose intravenous admi -
nistration of methotrexate (MTX) in the treatment of ma -
lignancies such as acute lymphoblastic leukaemia (ALL) has
been associated with cases of mild to severe neurotoxicity.
The pathogenic mechanism of neurotoxicity is not clear,
possibly MTX-associated biochemical alterations of the folate
and methyl-transfer metabolic pathways play an important
role. We report a case of an adult patient treated for ALL
relapse with signs of chronic leukoencephalopathy associated
with MTX administration. In order to assess alterations in the
folate and methyl-transfer pathway we determined 5-methyl -
te trahydrofolate (5-methyl-THF), S-adenosylmethi onine
(SAM) and S-adenosylhomocysteine (SAH) in the cerebro -
spinal fluid (CSF) of the patient. Three CSF samples were
obtained by lumbar punction within a four-month period.
Concentrations of the metabolites were measured using vali -
dated bioanalytical methods based on HPLC with UV and
fluorescence detection. The results showed two-fold lower 5-
methyl-THF levels (29.3–31.8 nmol/L) in all obtained sam ples
compared to reference values. SAM concentrations were even
more than five-fold lower in two samples (5–34.2 nmol/L).
SAH concentrations were in the range 7.5–14.3 nmol/L. Our
patient had pronounced alterations in the folate and methyl-
transfer pathway which indicate that MTX-associated bio -
chemical alterations of these pathways may play an important
role in the development of leukoence pha lopathy. 
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Case report
Intrathecal and/or high-dose (>1 g/m2) admini -
stra tion of methotrexate has been associated with neu -
rotoxicity (1, 2), which in terms of severity ranges from
mild and reversible to severe with possible fatal out -
come (3). According to time of appearance, neurot o xi -
city is classified as acute, subacute and chronic. Clinical
signs of chronic neurotoxicity may appear months to
years following MTX administration (4). This form of
neurotoxicity, although rare, is usually severe, char a c -
terized by leukoencephalopathy, demyelination, loss of
cerebral parenchyma (4, 5) and clinical signs such as
personality changes, progressive dementia, focal
seizures, spastic quadriparesis and stupor (4). Patients
may also develop learning disability, cognitive distur -
bances and decrease in intelligence (6, 7). Chro nic
MTX-associated neurotoxicity may resolve partially or
fully, but it may also persist and even progress to coma
and death (8, 9).
The pathogenic mechanisms of MTX-associated
neurotoxicity are not fully elucidated yet (10). It was
suggested that MTX-induced biochemical alterations
may play an important role in the development of
neurological complications (11).
MTX as an antifolate targets primarily the folate
pathway (see Figure 1) inducing the depletion of the
pool of tetrahydrofolates (THF). Accordingly, decrea -
sed levels of 5-methyl-THF were reported in the CSF of
patients who received high-dose or intraventricular
MTX (11, 12). However, the mechanism by which
folate depletion could induce neurotoxicity is unclear. It
is possible that other metabolic pathways which are
altered as a consequence of folate impairment may be
responsible for clinical signs of neurotoxicity. 
The folate metabolic pathway is directly linked to
the homocysteine-methionine conversion through 5-
met hyl-THF. The lack of methionine leads to a deple -
tion of the main methyl-donor S-adenosylmethionine
(SAM). SAM together with the methyl-transferase
inhibitor S-adenosylhomocysteine (SAH) forms the
methyl-transfer pathway which is necessary for
methylation and synthesis of the myelin sheath. Loss of
myelin disables the normal neuronal function which
could further lead to the development of cognitive
decline. Since severe demyelination and white matter
changes are main features of chronic MTX-associated
neurotoxicity, an impairment of the methyl-transfer
pathway may be involved in its pathogenesis. Moreover,
decreased SAM levels in the CSF were associated with
demyelination reported in patients with MTX-related
subclinical and clinical leukoencephalopathy (13, 14).
Furthermore, it was suggested that the SAM/SAH ratio
may be a better marker for leukoencephalopathy than
SAM alone (15). We report a case of a patient suffering
from chronic MTX-associated neurotoxicity presenting
with leukoencephalopathy, manifest signs of cognitive
disorder and personality change with a severe impa ir -
ment of the folate and methyl-transfer pathway.
Our patient was a 35-year old female with ALL
which was first diagnosed at the age of 17. At that time
she was treated with high-dose MTX accompanied by
cranial irradiation. At the age of 27, the first relapse
occurred and the patient was treated with high-dose
MTX (1 g/m2) and intrathecal MTX (12 mg) without
cranial irradiation. A total of nine high-dose infusions
and 60 mg intrathecal MTX were administered. At that
time no MTX-associated neurological complications
were observed. At the age of 35, she presented with
the second relapse and started receiving treatment
which did not include MTX. However, at this time-
point, cognitive decline, memory loss, confusion, de -
pres sed level of consciousness, personality change,
speech impairment and tremor were evident. The
evaluation of neurotoxicity was performed according to
Common Toxicity Criteria (CTC) and the results are
presented in Table I. Magnetic resonance imaging
(MRI) revealed severe leukoencephalopathy in both
brain hemisph e res. Circular lesions were also present,
however, asso ciated with an overt infection. 
According to a previously obtained approval of
the local ethics committee we were able to obtain CSF
samples when lumbar puncture was performed
diagnostically or due to the treatment protocol. Three
CSF samples were obtained within four months. The
third sample was obtained when the patient presented
with signs of toxicity probably due to a CNS infection.
She had severe headache and pain followed by high
fever. The CSF was yellow coloured indicating
hyperbilirubinemia which was later confirmed. 
In order to assess the folate pathway, 5-methyl-
THF was determined using a modified method by Belz
et al. (16) based on reversed-phase HPLC with si mul -
taneous UV and fluorescence detection. Methanol was
used for elution instead of acetonitrile. In brief, a
SupelcosilTM column (15 x 0.46 cm, 3 mm) and a
SupelguardTM precolumn (2 x 0.46 cm, 5 mm) both
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Figure 1 Metabolism of folates and methyl-transfer pathway.
Abbreviations: ATP: adenosine triphosphate; DHF: dihydrofolate;
SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; THF:
tetrahydrofolate; (1) dihydrofolate reductase; (2) serine-hydro xy -
methyltransferase; (3) 5,10-methylenetetrahydrofolate reductase; (4)
methionine synthase; (5) betaine-homocysteine methyltransferase;
(6) methionine adeno syltransferase; (7) R-methyltransferase; (8)
SAH hydrolase
from Supelco (Bellefonte, USA) were used as stationary
phase. The HPLC system was from Thermo Separation
Products, Inc (Egelsbach, Germany). Fifty mL samples
were injected onto the HPLC system and separated by
gradient elution which consisted of methanol and
phosphate buffer (10 mmol/L, pH 2.1). Fluorescence
detection (294/356 nm) was used, flow rate was
1 mL/min, retention time was 8.8 min. The method
was validated according to the FDA Guideline (17).
Due to the instability of reduced folates, CSF samples
were collected in vials containing an ascorbic acid
solution (5 mg/mL).
Determination of SAM and SAH in the CSF was
performed using HPLC with fluorescence detection. An
EclipseTM AAA column (15 x 0.46 cm, 5 mm) from
Agilent Technologies Inc., (Palo Alto, USA), and a Nu -
cleosilTM precolumn (2 x 0.46 cm, 5 mm) from Supelco
(Bellefonte, USA) were used as stationary phase. Fluo -
rescence detection of SAM and SAH was enabled by
derivatisation with 5.5 mol/L chloroacetaldehyde at pH
3.5–4.0, 39 °C for 16 h as described by Wagner et al.
(18). The formed 1,N6-etheno derivatives were eluted
on a reversed phase column especially designed for
separation of amino acids. Mobile phase consisted of
acetonitrile and an aqueous solution (pH 4.5) con -
taining 40 mmol/L of potassium dihydrogen pho s pha -
te and 8 mmol/L of the ion-pair reagent 1-hepta ne -
sulfonic acid. Analytes were separated by gradient
elution. The injection volume was 100 mL, at a con -
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Symptom Grade Description of severity according to CTC
Ataxia (incoordination) 3 Moderate symptoms interfering with activities of daily living
Cognitive disturbance 3 Cognitive disability resulting in significant impairment of work 
performance; cognitive decline > 2 SD*
Confusion 3 Confusion or delirium interfering with activities of daily living
Depressed level of consciousness 3 Obtundation or stupor; difficult to arouse; interfering with activities 
of daily living
Irritability 1 Mild, easily consolable
Leukoencephalopathy-
-associated radiological findings
2 Moderate ventriculomegaly; and/or focal T2 hyperintensities extending 
into centrum ovale; or involving 1/3 to 2/3 of susceptible areas of cerebrum
Memory loss 2 Interfering with function but not with activities of daily living
Mood alteration 1 Mild mood alteration not interfering with function
Depression 2 Interfering with function but not with activities of daily living
Neuropathic pain 3 Severe pain
Personality change 2 Change but not disruptive to patient or family
Speech impairment 2 Awareness of receptive or expressive dysphasia, not impairing the ability 
to communicate
Tremor 2 Moderate tremor, interfering with daily function but not interfering 
with activities of daily living
Table I CTC evaluation of neurotoxicity symptoms in the patient with chronic neurotoxicity.
* SD: standard deviation 
Table II CSF analysis of 5-methyl-THF, SAM and SAH in the neurotoxic patient and PCNSL patients with and without
neurotoxicity.
Concentration (nmol/L)
Sample 5-methyl-THF SAM SAH
Present case 











PCNSL patient with chronic neurotoxicity 13.5–22.7 34.1–54.7 5.7–11.2
PCNSL patients without neurotoxicity 59.2–91.5 182.4–966.6 5.1–11.0
stant flow rate of 1 mL/min and detection at 270/410
nm. Retention times were 19.7 and 23.5 min for SAH
and SAM, respectively. Five hundred mL of CSF were
collected with 100 mL of perchloric acid 1.2 mol/L
used to provide precipitation of proteins and to ensure
stability of the compounds. Samples were centrifuged
for 10 min at 15 500 x g and frozen at –20 °C. The
method was validated according to the FDA Guideline
for bioanalytical methods (17).   
CSF concentrations of 5-methyl-THF, SAM and
SAH of the patient with chronic neurotoxicity are pre -
sented in Table II. Our patient had approximately two-
fold lower CSF 5-methyl-THF concentrations compared
to normal CSF levels according to literature data (19,
20). Moreover, we previously reported CSF 5-methyl-
THF concentrations in adult patients with primary
central nervous system lymphoma (PCNSL) treated
with high-dose and intrathecal MTX (21). Our ALL
patient with chronic neurotoxicity had considerably lo w -
er CSF 5-methyl-THF concentrations compared to
PCNSL patients without neurotoxicity (see Table II).
Furt hermore, in the PCNSL population we had a pa -
tient with signs of chronic neurotoxicity and leuko -
encephalopathy with massive demyelination revealed
by MRI. Low 5-methyl-THF concentrations similar to
those found in the present case were observed in this
patient as well (Table II).
CSF SAM concentrations were at least five-fold
lower in two out of three samples compared to lite -
rature reference data (22). In the last sample the level
of SAM was rather high compared to the two previous
measurements. However, at that time-point the patient
exhibited hyperbilirubinemia and the CSF sample was
intensively yellow coloured. It cannot be excluded that
there was an interference with the fluorescence
determination of SAM. 
CSF SAM levels in the first two samples of our
present patient were also considerably lower compared
to PCNSL patients without neurotoxicity. Moreover,
present findings are similar to CSF SAM levels in the
PCNSL patient at the time of chronic neurotoxicity. In
contrast, CSF SAH levels in our patient were similar to
those of PCNSL patients where the level of the methyl-
transferase inhibitor ranged from 5.1–11.0 nmol/L
(21). Kishi et al. (15) also reported two cases with chro -
nic neurotoxicity who had low CSF SAM levels (74.8
and 79.3 nmol/L respectively). However, in contrast to
our findings, these authors also reported increased
SAH levels (27.5–34.3 nmol/L). 
In conclusion, a severe biochemical alteration of
the folate and methyl-transfer pathways was observed
in an ALL patient with chronic MTX-associated neuro -
toxicity. Since SAM is the most important methyl-donor,
the impairment of the methyl-transfer pathway which
resulted in more-fold decreased CSF SAM levels could
have played a crucial role in the pathogenesis of le uko -
encephalopathy. Further research is necessary to estab -
lish if monitoring of the 5-methyl-THF and SAM in the
CSF may help predict patients at risk of developing
signs of chronic neurotoxicity. Moreover, if the impair -
ment of the methyl-transfer pathway is respon sible for
demyelination, then substitutional therapy with SAM
may represent an option for preventing neuronal da -
ma ge and its consequences. 
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